1. Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group
- Author
-
D. Concolino, L. Amico, M.D. Cappellini, E. Cassinerio, M. Conti, M.A. Donati, F. Falvo, A. Fiumara, M. Maccarone, R. Manna, A. Matucci, M.B. Musumeci, A. Nicoletti, R. Nisticò, F. Papadia, R. Parini, D. Peluso, L. Pensabene, A. Pisani, G. Pistone, M. Rigoldi, I. Romani, M. Tenuta, G. Torti, M. Veroux, and E. Zachara
- Subjects
Fabry disease ,Enzyme replacement therapy ,Home treatment ,Adherence ,QoL ,Medicine (General) ,R5-920 ,Biology (General) ,QH301-705.5 - Abstract
Fabry disease (FD) [OMIM 301500] is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A, resulting in progressive multisystem accumulation of globotriaosylceramide (Gb3). Although the introduction of Enzyme Replacement Therapy (ERT) resulted in a variety of clinical benefits, life-long intravenous (IV) treatment with ERT with an every other week schedule, may interfere with daily life activities and impact on QoL. We report here a multicentric, observational, longitudinal data analysis on a large cohort of 85 Italian FD patients (45 males, 40 females) from 11 out of 20 Italian regions, who received a cumulative number of 4269 home infusions of agalsidase alfa. For the whole cohort, the average duration of home therapy was 1 year and 11 months (range 3 months–4 years and 6 months), and during this period, compliance to treatment (number of infusions performed vs scheduled) reached 100%. The EQ-5 VAS scale was administered to patients to evaluate the self-reported QoL, 58% of patients showing an increase of EQ-5 VAS score at follow up compared to baseline (home treatment start) or remaining stable. A mild increase of average disease severity, measured through Mainz Severity Score Index (MSSI), was found during hospital treatment (p
- Published
- 2017
- Full Text
- View/download PDF